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Introduction
∆ 9 -tetrahydrocannabinol (THC), the principal psychoactive ingredient in marijuana, produces euphoria and relaxation and impairs motor coordination, time sense and short-term memory (Ameri, 1999) . Clinically useful attributes of the cannabinoids (CBs) include their ability to produce analgesia, reduce chemotherapy-induced emesis, stimulate appetite, and attenuate seizures and spasticity (Croxford, 2003) . The central actions of CBs are mediated by activation of CB1 receptors located primarily on presynaptic nerve terminals, where they interact with heterotrimeric G proteins (G i /G o ) to inhibit neurotransmitter release via inhibition of voltage-gated Ca 2+ channels and activation of K + channels (Howlett et al., 2004) . Endocannabinoids (eCBs) are arachidonic acid derivatives produced in response to postsynaptic stimulation; they diffuse in a retrograde fashion across the synapse to act on presynaptic CB1 receptors to exert a similar inhibition of neurotransmitter release (Diana and Marty, 2004) .
Activation of CB1 receptors by either exogenous or endogenous ligands reduces the strength of the affected synapse. The eCB system mediates a long-term depression of projections from prefrontal cortex to nucleus accumbens neurons (Robbe et al., 2002) and long lasting autoinhibition of neocortical GABAergic interneurons (Bacci et al., 2004) .
In hippocampus, CBs inhibit GABA release from a subset of interneurons and inhibit glutamate release from principal neurons (Katona et al., 1999; Domenici et al., 2006) .
Thus, cannabinoids produce both rapid and long-term changes in synaptic transmission.
Cannabinoids protect hippocampal neurons from excitotoxicity (Shen and Thayer, 1998b) and from oxygen and glucose deprivation (Nagayama et al., 1999) . Cannabinoids also provide protection in a variety of models of acute neurodegeneration in vivo JPET #131607
5 (Nagayama et al., 1999; Panikashvili et al., 2001; van der Stelt et al., 2001 ). These effects have mostly been ascribed to inhibition of glutamatergic synaptic transmission (Shen et al., 1996; Gilbert et al., 2007) consistent with localization of CB1 receptors on glutamatergic nerve terminals (Domenici et al., 2006) . Indeed, the eCB system appears to serve as an on-demand mechanism to reduce excitatory synaptic activity and thus protect from over-stimulation (Marsicano et al., 2003; Alger, 2004) .
Changes in dendritic morphology accompany changes in synaptic strength (Harms and Dunaevsky, 2006) . Indeed, stimuli that induce long term potentiation of synaptic transmission alter the shape of synaptic spines (Carlisle and Kennedy, 2005) and increase the number of synapses (Ma et al., 1999) . Changes in dendritic morphology also appear in the early stages of neurodegenerative disorders . Dendritic spines undergo some of the earliest structural changes during excitotoxic injury to neurons (Olney et al., 1979) and changes in spine density are well documented in a variety of epilepsy models (Fiala et al., 2002) . Synaptic loss is not necessarily a step on the path toward death, but instead may be a mechanism that enables the cell to adapt to excessive excitatory input (Finkbeiner et al., 2006; Waataja et al., 2008) . If synaptic loss is a coping mechanism, then pharmacologic strategies to preserve network function may be important compliments to drugs that improve survival.
The postsynaptic density protein, PSD-95, is a scaffolding protein that anchors receptors and downstream signaling molecules to the postsynaptic density (Kim and Sheng, 2004) and is widely used as a marker for synaptic sites (Okabe et al., 1999) . PSD-95 is removed from synapses in response to stimuli that induce long term depression of synaptic transmission (Colledge et al., 2003) and during epileptic activity (Zha et al., JPET #131607 6 2005 
]cyclohepten-5,10-imine hydrogen maleate (MK801), Z-Leu-Leu-Leu-al (MG132) and all other reagents from Sigma (St. Louis, MO).
Cell culture. Rat hippocampal neurons were grown in primary culture as described previously (Shen and Thayer, 1998a) Transfection. Rat Hippocampal neurons were transfected between 10 and 13 days in vitro using a modification of a protocol described previously (Waataja et al., 2008) . JPET #131607
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Image processing. To count and label PSD95-GFP puncta an automated algorithm was created using MetaMorph 6.2 image processing software described previously (Waataja et al., 2008 
Results

Visualizing changes in synaptic sites
We developed an imaging-based method to quantify the number of synaptic sites on hippocampal neurons in culture based on the detection of clusters of the scaffolding protein PSD95 fused to enhanced green fluorescent protein (PSD95-GFP) (Waataja et al., 2008) . In Fig. 1 we show hippocampal neurons in culture that were transfected with expression plasmids for PSD95-GFP and DsRed2. Confocal imaging of transfected neurons was used to identify postsynaptic sites, as indicated by PSD95-GFP puncta ( 12 GFP fusion protein expressed in hippocampal pyramidal neurons was clustered at postsynaptic sites (Okabe et al., 1999) .
Aberrant excitatory synaptic activity induces the loss of synaptic sites
Reducing ] i spiking was driven by glutamatergic synaptic transmission as it was significantly reduced (68 ± 4 % inhibition, n=41) by treatment with the NMDA receptor antagonist MK801 (10 µM) ( suggest that intense excitatory synaptic activity causes the loss of synaptic connections.
We next determined the time course for changes in the number of PSD95-GFP puncta and cell survival. Survival was defined as the retention of cytoplasmic DsRed2 protein.
As shown in Fig. 2A , cell survival was stable for 24 hrs under control conditions and the number of PSD95-GFP puncta increased initially. The precise mechanism for this increase is not known, although the data in Figure 2C indicated that it develops in a graded fashion. It was triggered by the media exchange as experiments in which cells remain in growth media showed a significantly smaller increase (6 ± 5 % vs. 49 ± 10 %).
New synapse formation required protein synthesis because it was inhibited by cycloheximide (10 µ M) (-2 ± 13 %) but did not require synaptic activity as indicated by a lack of effect of tetrodotoxin (TTX) (40 ± 18 %). (Shen et al., 1996) . We tested the effect of cannabinoid agonists on 0.1 mM [Mg 2+ ] o -induced PSD loss. As shown in Fig. 3 (Fig. 4) . THC reduced the loss of PSD95-GFP puncta with an EC 50 of 9 ± 3 nM. WIN55,212-2 was more potent than THC with an EC 50 of 2.5 ± 0.5 nM.
WIN55,212-2 acts presynaptically
Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission by acting presynaptically to inhibit the release of glutamate (Shen et al., 1996) . To test whether the effects of cannabimimetic drugs on synaptic sites were mediated via actions at pre-or postsynaptic targets we examined the effects of WIN55,212-2 on changes in
PSDs evoked by treatment with glutamate. Application of glutamate (4 h, 100 µM) to cultured hippocampal neurons reduced the number of PSD95-GFP puncta by 63 ± 14 % (Fig. 5A) . In contrast to the effects of cannabimimetics on the synaptically-mediated PSD loss induced by 0.1 mM [Mg 2+ ] o , WIN55,212-2 did not prevent the PSD loss elicited by the direct application of glutamate (Fig. 5A) . Thus, cannabinoid receptor agonists act presynaptically to inhibit 0.1 mM [Mg 2+ ] o -induced PSD loss.
A presynaptic site of action for the CB1 agonists would be consistent with an JPET #131607
15 inhibition of N-and P/Q-type Ca 2+ channels (Shen and Thayer, 1998a 
Prolonged exposure to WIN55,212-2 diminishes the protection of PSDs by cannabinoids
Prolonged exposure to WIN55,212-2 or THC desensitized CB1 receptor-mediated inhibition of synaptic transmission (Kouznetsova et al., 2002; Lundberg et al., 2005 
Cannabinoids reverse synaptically driven synapse loss
If PSD loss proceeds via a path that is independent from that leading to cell death, then synapse loss might be reversible. We next examined whether WIN55,212-2 could reverse synaptically driven PSD loss following exposure to 0.1 mM [Mg 2+ ] o .
Hippocampal neurons expressing PSD95-GFP and DsRed2 were exposed to 0.1 mM [Mg 2+ ] o for 1 h which produced a 39 ± 6 % loss of PSDs (Fig. 7A, B (Fig. 7C) . Therefore, there is a window of at least 1 hr but less than 4 hr during which activation of CB1R can reverse synaptic loss resulting from epileptic patterns of synaptic activity.
Discussion
We used an in vitro model to quantify changes in the number of individual synapses in a synaptic network over time. The intense synaptic activity evoked by reducing [Mg 2+ ] o to 0.1 mM decreased the number of PSD95-GFP puncta by 45 ± 13 %. This observation is consistent with previous reports showing a decrease in spine density in hippocampal neurons exposed to glutamatergic agonists or epileptiform activity (Muller et al., 1993; Colledge et al., 2003; Zha et al., 2005) . Cannabinoids acted potently on presynaptic CB1 receptors to prevent or even reverse PSD loss that resulted from intense synaptic activation of NMDA receptors. Thus, presynaptic inhibition attenuated synaptic transmission sufficient to prevent long term changes in the number of synapses.
Cannabinoid modulation of synapse loss desensitized, raising interesting questions about the changing role of the endocannabinoid system in neuroprotection following chronic exposure to drugs. PSD loss is an early event in neurodegenerative disease; its reversal by cannabinoids has implications for protection of network function, modulation of synaptic plasticity and regulation of neuronal survival.
We used PSD-95, a protein that serves as a scaffold for assembling signaling molecules at excitatory synapses, as a marker for synapses between hippocampal neurons in culture. Glutamate produces a local [Ca 2+ ] i increase at PSD95-GFP puncta, these puncta are in close apposition to presynaptic sites of vesicular release and they colocalize with NR2A and 2B immunoreactivity (Waataja et al., 2008) . Thus, PSD95-GFP puncta represented functional postsynaptic sites. The formation and loss of synaptic puncta were highly dynamic, consistent with previously reported high turnover rates for synapses in culture (Okabe et al., 1999) . The increase in synaptic number induced by JPET #131607
19 media exchange required protein synthesis. Thus, the increase was not an imaging artifact, but instead was a physiological response to the experimental protocol. The increase did not impede quantitative analysis and statistical testing of hypotheses because it was reproducible and in the opposite direction from activity-induced changes.
Epileptic activity induced a robust loss of puncta that was highly reproducible and statistically different from the control conditions. This loss was seen in PSDs located on dendritic shafts and spines. Zha et al (2005) have described a similar activity-induced loss of PSDs on spines but in their study TTX induced a loss of PSDs on dendritic shafts.
The dissociated cultures used in this study were derived from fetal animals whereas Zha et al (2005) used postnatal slice cultures. Overall, our data are in good agreement with previous studies that found a loss of excitatory synapses associated with epileptic activity (Muller et al., 1993; Colledge et al., 2003; Zha et al., 2005) ; we extended these previous studies to show pharmacological modulation of the process by cannabinoids. This assay was particularly well-suited to detect the recovery of synapses following loss because quantitative data could be obtained from the same cell over time. Loss of synaptic puncta was dependent on activation of NMDA receptors and mediated by the ubiquitinproteasome pathway, in good agreement with a study showing that PSD-95 is ubiquitinated and rapidly removed from synaptic sites in response to NMDA receptor activation (Colledge et al., 2003) . Thus, intense synaptic activity leads to proteasomemediated loss of PSD95-GFP from synaptic sites.
Loss of postsynaptic proteins and dendritic spines are early events in many neurodegenerative disorders (Gylys et al., 2004) . Loss of synaptic terminals in the brains of Alzheimer's patients more closely correlates with decreased cognitive function than JPET #131607 20 cell death, supporting the hypothesis that disappearance of synapses is a key event in early cognitive decline (Terry et al., 1991) . Here we showed that intense glutamatergic synaptic activity decreased the number of synapses long before cells succumbed to excitotoxic death. This loss was reversible and mediated by the ubiquitin-proteasome pathway, attributes not generally associated with cell death pathways. Synapse loss may be a coping mechanism that is distinct from cell death processes because loss of PSDs appears to protect neurons from over-stimulation and subsequent toxicity (Waataja et al., 2008) . Loss of synaptic function as a result of degenerative disease, pharmacologic block of NMDA receptors or cannabinoid inhibition of glutamate release, all produce cognitive impairment and all appear to improve neuronal survival during excitotoxic insult. Thus, neuroprotective strategies need to balance protecting PSDs, which can exacerbate overstimulation of the postsynaptic cell, with allowing synapse down regulation, which may improve survival at the cost of reduced participation in the synaptic network.
Here we showed for the first time that inhibiting presynaptic Ca 2+ channels either directly or by activation CB1 receptors prevented synapse loss resulting from epileptic activity. Ca 2+ channel blockers are neuroprotective in some models of neurodegeneration (Valentino et al., 1993) and cannabinoids have antiepileptic properties (Croxford, 2003; Marsicano et al., 2003) . However, this is the first report to show that either class of compounds protects network integrity from an excitotoxic insult. As a neuroprotective strategy drugs that inhibit glutamate release have the advantage of both preventing synapse loss and improving survival. A disadvantage of this approach is the potential for psychoactive side effects.
Cannabinoids acted potently on presynaptic CB1 receptors to prevent excitotoxic JPET #131607 21 synapse loss. These actions were in good agreement with previous reports from our laboratory (Shen et al., 1996; Shen and Thayer, 1999) and others (Hajos et al., 2001) showing cannabinoid inhibition of glutamatergic synaptic transmission. The reversal of the protective actions of the cannabinoids by rimonabant suggests that this drug might modify seizure threshold and network function in circuits with strong eCB tone (Marsicano et al., 2003) . Interestingly, THC completely blocked PSD loss even though it reduces synaptic activity by less than 50 % (Shen and Thayer, 1999) , consistent with the idea that attenuation without complete block is sufficient to protect synaptic sites. This finding and the observation that the network displays a modest level of synaptic activity under control conditions suggest that the loss of PSDs requires sustained intense synaptic activity. Reducing [Mg 2+ ] o to 0.1 mM evoked an aberrant pattern of synaptic activity that approximates epileptic discharges (McLeod et al., 1998) . Down regulation of synapses may underlie long term depression of synaptic transmission (Colledge et al., 2003 ) in which case the threshold level of activity to induce PSD loss would presumably not be toxic. Perhaps the dramatic synapse loss described here in response to intense stimulation and the sustained moderate activity required to induce LTD lie on a continuum of activity that produces corresponding changes in synaptic input to stabilize neuronal excitability (Desai, 2003) .
The cannabinoid receptor agonist WIN55,212-2 reversed the synaptic loss induced by 0.1 mM [Mg 2+ ] o in the continued presence of the excitatory stimulus. This observation suggests that pharmacologic treatments might be used to improve or protect network function independent of treating the underlying cause of the synaptic loss. We speculate that protecting synapses might be important to pursue in parallel to strategies JPET #131607 22 aimed at improving survival. Thus, the effective protection of synapses by cannabinoid agonists and calcium channel blockers suggests that network protection is in principle a reasonable approach. It will be interesting to evaluate other targets for synapse protection such as inhibition of postsynaptic proteolysis. If synapse loss is indeed a coping strategy then synapse protection may increase the risk of excitotoxicity and thus, will need to be part of an approach that also improves survival. Our results also indicate that there is a window during which synapse loss can be reversed. The cell culture model employed for these studies is highly dynamic and would appear to undergo changes more rapidly than synapses studied in vivo (Grutzendler et al., 2002) . Thus, the opportunity to protect network function may be longer in vivo where both loss and recovery may proceed on a slower time scale. Clearly more in vivo studies of synaptic loss and recovery are warranted.
Cannabinoid-induced presynaptic inhibition of glutamatergic neurotransmission desensitizes after prolonged exposure to CB1 receptor agonists (Lundberg et al., 2005) .
Prolonged exposure to WIN55,212-2 diminished the protective effect of cannabimimetic drugs. However, even when tested at a maximally effective concentration, the desensitization produced by THC was less pronounced than that produced by WIN55,212-2. Thus, THC exerted a longer lasting modulation of synaptic function than the more potent and efficacious agonist. Interestingly, chronic WIN55,212-2 treatment did not itself affect the number of synapses (Fig. 6 ), but instead prevented subsequent protection afforded by CB1 receptor agonists (Fig. 6) . Thus, prolonged exposure to cannabinoid agonists might diminish on-demand protection of synapses mediated by eCBs. These observations suggest that therapeutic strategies that enhance eCB function JPET #131607 23 without chronic CB1 receptor activation, for example by inhibiting metabolism, might prove most effective for long-term protection of synaptic function. This approach would also avoid the desensitization that accompanies prolonged exposure to agonists.
In conclusion, we showed that intense excitatory synaptic activity decreases synapses between hippocampal neurons and that attenuation of this activity by cannabinoids prevented synapse loss. Excitatory neurons maintain a precarious balance between full integration into excitatory networks, with the associated risk of overstimulation, and withdrawal from the network to increase survival, with the associated loss of network function. Modulation of presynaptic CB1 receptors either directly or through modulation of the eCB system may prove to be a useful pharmacologic approach for maintaining this balance during neurodegenerative disease.
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